Trinity Delta Lighthouse: Redx Pharma
Trinity Delta view: We believe Redx Pharma has an attractive, and well balanced, clinical portfolio; an enviable track record of delivery; and well-respected management. In our September 2020 Initiation we described Redx’s strategy of developing either “first in class” or “best in class” compounds and how the two lead assets, the porcupine inhibitor RXC004 in oncology and ROCK2 inhibitor RXC007 for fibrosis indications, are set to progress to key proof of concept trials. The new funds provide the resources to maintain the momentum of the existing clinical pipeline, in particular allowing for completion of the RXC004 Phase II programme, and to progress earlier stage assets. Our prior Redx valuation of £296m, or 152p per share (92p fully diluted), and our published forecasts will be updated to reflect the fundraise as soon as practicable.Redx Pharma is engaged in drug discovery, pre-clinical development and licensing. The principal activities of the business are the discovery and development of proprietary, small molecule drugs to address areas of high, unmet medical need. Co. is developing a porcupine inhibitor drug candidate, RXC004, as a cancer treatment using in vivo models of pancreatic and gastric cancer. ROCK1/2 inhibitors (known as systemic pan-Rock inhibitors) are known to induce hypotension. Co.'s ROCK inhibitor is designed to only work at the site of action in the gastrointestinal tract and degrades quickly, once absorbed, through enzyme-mediated metabolism in the blood, deeming it a soft inhibitor.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.